Your Article Summary
Teva announces agreement on allegra patent challenge
Teva Pharmaceutical Industries, 11/20/08
Teva Pharmaceutical Industries Ltd. announced that its subsidiary, Teva Pharmaceuticals USA, Inc., and Barr Laboratories, Inc. have signed an agreement with Aventis Pharmaceuticals, Inc., sanofi-aventis U.S. LLC and Albany Molecular Research, Inc. to settle patent litigation involving Teva's and Barr's U.S. generic versions of Aventis Pharmaceuticals' Allegra (fexofenadine) 30mg, 60mg and 180mg tablets including all claims for patent infringement and damages. After entering into a separate agreement with Barr, Teva launched its generic fexofenadine tablets in the U.S. in September 2005.
Today in M&A/Partnerships...keeping you current
Receive free subspecialty "5-minute updates" via email
Omnicell Gets Cabinet Deal in Carolinas
HealthDataManagement, 12/16/09
Array BioPharma and Amgen Partner in Type 2 Diabetes
Amgen, 12/15/09
Inno Biologics and CEVEC Sign License Agreement for Human CAP Technology
b3c newswire, 12/09/09
Article Search
Sponsor


See Latest Articles


